That caught my attention too. Such a quiet stock I'm not sure its much of a trader most of the time though.
Hopefully its not a case of underwhelming Q2 sales growth. At historical rate of cash burn, by Q4 we will be back at similar cash levels to where we raised cash in Q4 last year. Growth in Pharmacy customers (and in turn sales) is what will prolong the cash burn. If we can grow enough customers/sales in Q2/Q3 we may be able to delay the need for a CR (potentially indefinitely)
~85% of revenue is through Pharmacy sales channel. As at last quarterly, less than 20% of pharmacies covered. Plenty of opportunity for expanding pharmacy sales to prolong the need for a CR. Here's hoping the agreement with In2Pharma back in February starts to show some growth in pharmacy customers during Q2.
BDA Price at posting:
52.0¢ Sentiment: Buy Disclosure: Held
